Literature DB >> 35348617

MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Chiara Cioccarelli1,2, Barbara Molon1,2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous subset of cells expanded during multiple pathological settings, including cancers. In tumors, MDSCs are dominant drivers of T-cell immunosuppression. To accomplish their job, they exploit multiple mechanisms ultimately leading to the paralysis of anti-tumor immunity. Among the variety of MDSC-ways of working within the tumor microenvironment, the generation of reactive species and the metabolic reprogramming have emerged as pivotal determinants of their immunosuppressive power. In this review we will overview integral mechanisms of MDSC-mediated immunosuppression in solid tumors, with a particular focus on Non-Hodgkin lymphoma.
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MDSC; T cell; cancer; immunotherapy; metabolism

Mesh:

Year:  2022        PMID: 35348617      PMCID: PMC9188344          DOI: 10.1093/cei/uxac025

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  120 in total

1.  Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.

Authors:  Chongyang Wu; Xiangyang Wu; Xiaoni Zhang; Ye Chai; Qi Guo; Lijuan Li; Lingling Yue; Jun Bai; Zhiping Wang; Liansheng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

Review 3.  Cytokine-like Roles for Metabolites in Immunity.

Authors:  Zbigniew Zasłona; Luke A J O'Neill
Journal:  Mol Cell       Date:  2020-04-24       Impact factor: 17.970

Review 4.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Michael Byrne; Olalekan O Oluwole; Bipin Savani; Navneet S Majhail; Brian T Hill; Fredrick L Locke
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

5.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

6.  Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells.

Authors:  Nataŝa Obermajer; Pawel Kalinski
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

Review 7.  The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

Authors:  Francesco De Sanctis; Sara Sandri; Giovanna Ferrarini; Irene Pagliarello; Silvia Sartoris; Stefano Ugel; Ilaria Marigo; Barbara Molon; Vincenzo Bronte
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

Review 8.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Authors:  Vincenzo Bronte; Sven Brandau; Shu-Hsia Chen; Mario P Colombo; Alan B Frey; Tim F Greten; Susanna Mandruzzato; Peter J Murray; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Paulo C Rodriguez; Antonio Sica; Viktor Umansky; Robert H Vonderheide; Dmitry I Gabrilovich
Journal:  Nat Commun       Date:  2016-07-06       Impact factor: 14.919

9.  Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.

Authors:  R-M Amini; G Enblad; P Hollander; S Laszlo; E Eriksson; K Ayoola Gustafsson; A Loskog; I Thörn
Journal:  BMC Cancer       Date:  2019-04-05       Impact factor: 4.430

Review 10.  TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment.

Authors:  Roberta Angioni; Ricardo Sánchez-Rodríguez; Antonella Viola; Barbara Molon
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

View more
  2 in total

1.  Metabolites: fuelling the immune response.

Authors:  Corrado Mauro; Moreira Diana; Jones Nicholas
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 2.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.